Commit Biologics Raises €54Mn in Seed Funding to Develop Cancer and Autoimmune Disease Treatments
Nov 17, 2026 | By Oliver Bennett

Copenhagen-based biotech startup Commit Biologics has raised €54 million ($60 million) in a Seed funding round. The company is developing new treatments for cancer and autoimmune diseases.
SUMMARY
- Copenhagen-based biotech startup Commit Biologics has raised €54 million ($60 million) in Seed funding.
- The funding round was led by Ackermans & van Haaren.
- New investors included AbbVie Ventures and M Ventures, alongside existing investors Bioqube Ventures, Korys and Novo Holdings.
- Founded in 2021, the company aims to develop a new approach to immunotherapy that does not rely on T cells.
The new investment will help Commit Biologics move its first drug candidate closer to clinical trials. These trials will help test the treatment's safety and effectiveness in people.
The funding round was led by Ackermans & van Haaren. New investors AbbVie Ventures and M Ventures also joined the round, along with existing investors Bioqube Ventures, Korys and Novo Holdings.
“Commit was founded on a simple idea: that complement, one of the most powerful parts of our immune system, could be deliberately directed against diseased cells. With this financing, we will take COM002, a first-in-class immune engager that works independently of T cells, into the clinic and build the foundation for complement-powered immune engagers to become a new pillar of immunotherapy,” says Dr. Thomas L. F. Montgomery Andresen, CEO of Commit Biologics.
RECOMMENDED FOR YOU
CERPRO Raises €2M Pre-Seed To Revolutionize Manufacturing Quality
Kailee Rainse
Nov 12, 2025
UK Quantum Startup QFX Secures €2.2 Million To Advance Modular Hardware Platform
Kailee Rainse
Oct 24, 2025
[Funding alert] Berlin-based Startup Pliant Raises €8 Million in Series A Round Funding
Oliver Bennett
Jan 16, 2024
Charlotte Kremers, Principal at M Ventures, says: “Complement is among the immune system’s most potent effector mechanisms yet remains largely untapped in drug development. Commit has made it programmable in a standard antibody, creating a path to medicines with differentiated efficacy and safety profiles across indications.”
Lenny Van Steenhuyse, Investment Manager at Ackermans & van Haaren, adds: “We firmly believe that Commit’s novel drug platform has the potential to generate a new treatment paradigm in immunotherapy based on the highly compelling preclinical data in targeted cell depletion. Ackermans & van Haaren is proud to support the Commit team and lead this financing to realise the full potential of the BiCE platform.”
Founded in Copenhagen in 2021, Commit Biologics is developing a new type of immunotherapy. Its approach uses the body's natural immune system to fight diseases.

The company has developed a technology called Bispecific Complement Engager (BiCE). It helps the immune system identify and destroy harmful cells, including cancer cells.
The technology works by bringing a protein called C1q to diseased cells. This activates the body's natural defence system and helps it attack those cells. Unlike some existing treatments, this approach does not rely on T cells to destroy diseased cells.
Read Also- Fermat Secures $8Mn Seed Funding to Expand AI Tools for Fashion Industry






